GA‑map® MHI GutHealth Test
Gut Microbiome Dysbiosis Analysis
A Breakthrough in Microbiome Health Analysis:
Measure the Need for and Impact of Microbiome Restoration Therapy
Pangea Laboratory, a CLIA‑certified and CAP‑accredited facility, is proud to be the only laboratory in the US to offer GA‑map® MHI GutHealth as a Research Use Only (RUO) test, in collaboration with Genetic Analysis AS. This advanced molecular test quantifies antibiotic‑induced gut microbiome imbalances using the Microbiome Health Index™ (MHI) and supports research and innovation in conditions where gut dysbiosis plays a critical role.
What is GA‑map® MHI GutHealth Testing?
The GA-map® platform is a pre-selected target multiplex technology allowing simultaneous analysis of a large number of bacteria in a single reaction. The technology utilizes 16S rRNA gene sequence variations between different bacteria groups or species for detection and quantification. Highly specific probes target their respective DNA sequence, allowing species-level resolution.
The GA-map® MHI Gut Health test is the first microbiome-based diagnostic test providing clinically actionable insights into antibiotic-induced microbiome imbalances. It combines the GA-map® technology with the validated Microbiome Health Index™ (MHI)1 and is demonstrated in recurrent Clostridioides difficile (rCDI) infected patients.
Sample Collection and Workflow
Sample Type: Stool Technology: 16S rRNA analysis with MagPlex® microsphere and Luminex instrument readout Throughput: 96‑well format for high‑volume processing Storage: Samples stable at ‑15 °C Result Reporting: Result reporting with the GA-map® MHI Gut Health test includes the MHI score (scale from 1-6) Turnaround Time: Results provided within 72 hours of sample receipt
Research Applications of GA‑map® MHI GutHealth Testing
The GA-map® MHI GutHealth test is an advanced tool for researchers investigating the critical role of the gut microbiome in health and disease. By utilizing the research-validated MHI biomarker, the test quantifies the ratio between pro- and anti-inflammatory bacterial groups in the gut. The test has been validated in cohorts of patients with recurrent Clostridioides difficile infection (rCDI), demonstrating excellent separation between patients before and after microbiome restoration treatment.
The test provides an MHI score on a scale from 1 to 6, where a low MHI indicates antibiotic-induced disruption of the gut microbiome. For research teams, the test provides a rapid and reliable method to establish a baseline profile of gut dysbiosis and to monitor shifts over time, particularly during interventions such as antibiotic therapy, fecal microbiota transplantation (FMT), dietary modification, or probiotic supplementation. Because the results are standardized and reproducible across studies, GA-map® MHI facilitates consistent data collection, enabling meaningful comparisons within and between research cohorts.
Beyond infectious diseases such as rCDI, the GA-map® MHI GutHealth test supports a broad range of translational and clinical research areas, including Graft-versus-Host Disease, immunocompromised patients, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), oncology, and metabolic disorders. Researchers can leverage the test to explore correlations between microbiome imbalance and immune response, treatment efficacy, or patient outcomes, making it a powerful tool for hypothesis generation and validation.
Importantly, the test is non-invasive, requiring only a simple stool sample, and offers fast turnaround times that allow researchers to integrate microbiome data into time-sensitive clinical workflows. This combination of ease of use, rapid results, and scientific rigor positions GA-map® MHI GutHealth test as a key technology for advancing microbiome-focused research and driving new discoveries in precision medicine.
Why Choose Pangea Laboratory?
Pangea Laboratory is the exclusive U.S.-based partner of Genetic Analysis AS offering the GA‑map® MHI GutHealth test. As a CLIA-certified and CAP-accredited laboratory, we deliver high-quality, reproducible results with rapid turnaround times to support both clinical research and innovation.
Our partnership ensures U.S. researchers and healthcare providers have direct access to this advanced microbiome testing technology without the need for international sample shipping or extended processing timelines. With proven expertise in molecular diagnostics, microbiome analysis, and collaborative research programs, Pangea Laboratory is uniquely positioned to provide reliable testing and expert support for studies focused on gut health and dysbiosis.
To Learn More, Contact Us Today
CONTACT
Learn More About GA‑map® MHI GutHealth Today
Discover how GA‑map® MHI GutHealth testing can support your research or clinical program. Contact Pangea Laboratory to request testing, explore partnership opportunities, or speak with our experts about integrating microbiome health analysis into your workflow. Our team is ready to help you access fast, reliable, and actionable insights to advance your work in gut health and microbiome research.
References
1. Blount K, Jones C, Walsh D, Gonzalez C and Shannon WD (2022) Development and Validation of a Novel Microbiome-Based Biomarker of Post-antibiotic Dysbiosis and Subsequent Restoration. Front. Microbiol. 12:781275. doi: 10.3389/fmicb.2021.781275
https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.781275/full